• English
  • Korean
  • Chinese
市場調査レポート - 138803

外傷性脳損傷:治療・診断パイプラインと商業的展望

Traumatic Brain Injury: Therapeutic and Diagnostic Pipeline Assessment and Commercial Prospects

発行 Arrowhead Publishers
出版日 ページ情報 英文
価格
外傷性脳損傷:治療・診断パイプラインと商業的展望 Traumatic Brain Injury: Therapeutic and Diagnostic Pipeline Assessment and Commercial Prospects
出版日: 2014年10月21日 ページ情報: 英文
概要

外傷性脳損傷(TBI)は幼児および若年成人層の死亡および障害の怪我に次ぐ主要な原因となっています。過去30年に渡って重点的に研究開発が行われてきたのも関わらず、研究から臨床への移行は依然として大きな課題として残されています。過去20年の間に行われた神経保護薬の有効性を検証する33回の第III相試験はすべて失敗に終わっており、その結果、FDA承認薬も存在していません。しかし米国では2013年、TBIのアンメットニーズを解消するためにNRAP(National Research Action Plan)が創出され、いくつかのポイントオブケア診断デバイスが2014年末までにはFDAから承認を得られる見通しです。

当レポートでは、外傷性脳損傷に関する研究開発動向について包括的に分析し、TBIの診断・治療の現状、TBI管理の困難さ、TBIのアンメットニーズ、治療薬および診断デバイスのパイプライン動向、TBIの潜在的市場の展望、主要事業者の取り組み、プロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 調査方法

  • 外傷性脳損傷:イントロダクション
  • TBIの明確で簡潔な定義はない
  • TBIは広範な類型を持つ複雑な障害
    • 一次性TBI
    • 二次性TBI
    • 局所性TBI
    • びまん性TBI
    • 開放性TBI
    • 閉鎖性TBI
  • 転倒がTBIの主要原因
  • 特異的症状がTBIの兆候となる
  • 2段階の病理学的ステージがある
  • TBIの診断検査に確立されたものはない
  • TBIの病期分類:脳損傷重症度により決定される
    • 軽度TBI
    • 中度TBI
    • 重度TBI
    • TBI患者人口の大部分は軽度TBI
  • TBIの予後の予想は困難
  • 重度TBIの予後は特に困難

第3章 TBIの疫学と財政的影響

  • 主要7カ国市場におけるTBIの疫学
  • TBIの大きな財政的影響

第4章 現在のTBI管理

  • TBIの管理
  • 軽度TBIの急性合併症が主要懸念材料
  • 中度・重度TBIの管理:二次的な怪我の回避を目的とする
  • 薬理的治療:TBI合併症後のコーナーストーンを形成
  • TBIのリハビリテーション:複数の治療アプローチを併用

第5章 TBIのR&Dにおける主要課題

  • 神経保護薬の第III相臨床試験における失敗
  • TBI研究のビジョン
  • オバマ政権によるNational Research Action Plan
  • TBI臨床試験における課題
    • TBI罹患人口の不均一性
    • 臨床試験設計
    • TBIのIMPACT(International Mission on Prognosis and Clinical Trials)提言
  • TBI研究の代替的アプローチ
    • TBIのシステムバイオロジー研究
    • TBIの比較有効性研究
  • R&Dを支援するTBIバイオマーカーの可能性
    • TBIのプロテオミクスベースのバイオマーカー発見
    • TBIの診断・患者モニタリングプラットフォームの開発
    • TBIのR&Dにおけるセラノスティクス(診断/治療の融合)の可能性
  • 法規制上の課題
  • 倫理的課題

第6章 TBI市場でのアンメットニーズ

  • TBIの共通の定義の欠如
  • 確立された診断テストの欠如
  • 軽度TBI:診断が不十分
  • TBI管理は標準化されていない
  • 承認された治療薬がない
  • 十分な治療を受けていない高齢患者
  • 大手製薬/バイオテクノロジー会社によるTBI分野への投資の不足
  • 国際的な協力・提携が必要

第7章 TBI治療薬のパイプライン分析

  • イントロダクション
  • BHR PharmaのBHR-100KKKKK (Progesterone)
  • Teva Pharmaceuticals/Cephalonの Nuvigil (Armodafinil)
  • Key Neurotek PharmaceuticalsのKN38-7271
  • Neuren PharmaceuticalsのNNZ-2566
  • NNZ-2566の商業化の可能性
  • Neurohealing Pharmaceuticalsの NH001 (Apomorphine)
  • Neurovive PharmaceuticalsのNEUROSTAT (Ciclosporin-A)
  • Oxygen Biotherapeuticsの Oxycyte (Perflurocarbon Oxygen Carrier)
  • VasopharmのVAS203
  • Remedy PharmaceuticalsのRP-1127

第8章 主要学術的研究・政府機関によるTBI研究:概要

  • イントロダクション
  • 主要候補薬の薬剤クラス:レビュー
    • アセチルコリンエステラーゼ阻害剤
    • エリスロポエチン
    • 成長ホルモン
    • 幹細胞
  • 新しいTBI薬の標的発見のための学術研究
    • FLAP(5-リポキシゲナーゼ活性化タンパク)阻害剤
    • プリン受容体アンタゴニスト
    • 炎症性サイトカイン阻害剤
    • システインプロテアーゼ阻害剤
    • 軽度TBIの革新的な動的イメージング研究に使用されるグルタチオンの経頭蓋送達
    • 末端補体経路のMAC(膜侵襲複合体)
  • 米国政府機関による新しいTBI薬標的の発見のための研究

第9章 潜在力のあるTBIバイオマーカー

  • イントロダクション
  • S100 B Caclcium結合タンパク質
  • 神経特異エノラーゼ(NSDE:Neuron Specific Enolase)
  • GFAP(グリア繊維性酸性蛋白)
  • NFL(Neurofilament Light Protein)
  • スペクトリン分解生成物
  • βアミロイドタンパク質(AB)
  • ミエリン塩基性タンパク質(MBP)
  • ユビキチンカルボキシル末端加水分解酵素アイソザイムL1(UCH L1)
  • タウタンパク質
  • Amparペプチド/GLUR1
  • TBIバイオマーカーアッセイサービス
    • Grace Laboratories
    • Banyan Biomarkers

第10章 TBIのPOS診断デバイスのパイプライン分析

  • イントロダクション
  • Luoxis Diagnostics/Ampio PharmaceuticalsのRedoxsys Diagnostic System
  • Banyan Biomarkersの UCH-L1/GFAP検出アッセイ
  • BiodirectionsのTbit Test Platform
  • SFC FluidicsのTBI診断プラットフォーム
  • BrainscopeのAhead M-100
  • CeroraのMindreader Biosensor Biomarker Program
  • ELMindAのBNAプラットフォーム
  • Neuro Assessment SystemsのNeuro-Screen

第11章 潜在的TBI市場の財務予測

  • 潜在的治療TBI市場:Arrowheadによる分析
  • TBIの潜在的POC診断デバイス市場に関する分析
  • SWOT分析
  • 潜在的TBI市場:サマリー

第12章 企業概要

  • Banayan Biomarkers Inc.
  • BHR Pharma LLC
  • Biodirection Inc.
  • Brainscope Company Inc.
  • Cerora Inc.
  • ElMindA Ltd.
  • Grace Laboratories LLC
  • KeyNeurotek Pharmaceuticals AG
  • Luoxis Diagnostics
  • Neuro Assessment Systems
  • Neurohealing Pharmaceuticals
  • Neuren Pharmaceuticals Ltd.
  • Neurovive Pharmaceuticals AB
  • Oxygen Biotherapeutics Inc.
  • Phlogistix LLC
  • Remedy Pharmaceuticals Inc.
  • SFC Fluidics LLC
  • TEVA Pharmaceutical Industries Ltd.
  • Vasopharm

第13章 文献

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Traumatic brain injury (TBI) is the single leading cause of death and disability worldwide in children and young adults following an injury. With around 10 million new cases diagnosed and 1.5 million deaths occurring per annum globally; this ‘silent' epidemic accounts for more fatalities than diabetes or lung cancer.

Despite three decades of intensive research and development effort, translating benchside to bedside success remains the single greatest challenge in TBI. All 33 Phase III TBI clinical trials testing the efficacy of neuroprotective agents have failed over the past 20 years. Consequently, no FDA-approved TBI therapy exists.

Nevertheless, 2013 witnessed the creation of a National Research Action Plan (NRAP) to address the current unmet needs in TBI. Point-of-care (POC) diagnostic devices look set to revolutionize the diagnosis of TBI. By year end 2014, a number of POC diagnostic devices may be approved by the FDA.

Key Features:

  • Identification of the major challenges within TBI R&D including unmet needs, clinical trial design and alternative R&D approaches, the potential of biomarkers, regulatory hurdles and ethical issues
  • Clinical and commercial analysis of key Phase III TBI drug candidates and point-of-care diagnostic devices
  • An assessment of the potential financial TBI market, with seven major market forecasts to 2020 for key pipeline drug candidates and point-of-care diagnostic devices

Purchase of this report will enable you to:

  • Assess opportunities and challenges influencing strategic TBI R&D
  • Identify key TBI drug candidates and point- of-care diagnostic devices in late-phase development based on sales forecasts to 2020
  • Gain an impartial perspective of strategies that can be used to enhance commercial success

Key questions answered:

  • What are the major unmet needs in the treatment of TBI?
  • What are the leading potential TBI biomarkers?
  • Who are the key specialist players involved in the TBI market and what business models are they using to raise company performance?
  • What lessons can investors learn from failed TBI drug candidates?
  • How can companies optimize strategic TBI R&D to maximize commercial success?
  • What are the key leading drug candidates in the TBI pipeline?
  • What are the key leading point-of-care diagnostic devices in the TBI pipeline?
  • What are the anticipated revenues for key pipeline drug candidates?
  • What are the anticipated revenues for key pipeline point-of-care diagnostic devices?

Table of Contents

1. EXECUTIVE SUMMARY

  • 1.1. Scope of Traumatic Brain Injury Research and Development Highlights 2014
  • 1.2. Methodology
  • 1.3. Traumatic Brain Injury is the Leading Cause of Death and Disability Following an Injury
  • 1.4. Supportive Management Forms the Cornerstone of TBI Treatment
  • 1.5. Failure of Over 30KKKKK Phase III Trials Presents Major Research and Development (R&D) Challenges in TBI
  • 1.6. There are Numerous Unmet Needs in TBI
  • 1.7. The Late-Stage Therapeutic TBI Pipeline is Limited
  • 1.8. Emerging TBI Diagnostic Products
  • 1.9. Financial Analysis of the Potential TBI Market

2. TRAUMATIC BRAIN INJURY: DISEASE BACKGROUND

  • 2.1. An Introduction to Traumatic Brain Injury
  • 2.2. There is No Clear, Concise Definition of TBI
  • 2.3. TBI is a Complex Disorder with a Range of Typologies
    • 2.3.1. Primary TBI
    • 2.3.2. Secondary TBI
    • 2.3.3. Focal TBI
    • 2.3.4. Diffuse TBI
    • 2.3.5. Open TBI
    • 2.3.6. Closed TBI
  • 2.4. Falls are the Leading Cause of TBI
  • 2.5. Specific Symptoms are Indicative of TBI
  • 2.6. Two Pathological Stages are Involved in TBI
  • 2.7. There is No Gold-Standard TBI Diagnostic Test
    • 2.7.1. Glasgow Coma Score
    • 2.7.2. Rancho Los Amigos Scale
    • 2.7.3. Westmead Post Traumatic Amnesia (PTA) Scale
  • 2.8. The Staging of TBI is Dependent Upon Brain Injury Severity
    • 2.8.1. Mild TBI
    • 2.8.2. Moderate TBI
    • 2.8.3. Severe TBI
    • 2.8.4. The Majority of the TBI Patient Population Sustain Mild Brain Injuries
  • 2.9. Predicting the Prognosis of TBI is Difficult
    • 2.9.1. Glasgow Outcome Scale
    • 2.9.2. Disability Rating Scale
    • 2.9.3. The NIH's International Mission for Prognosis and Clinical Trial (IMPACT) Prognosis Model
    • 2.9.4. The MRC's Corticosteroid Randomization After Significant Head Injury (CRASH) Prognosis Model
  • 2.10. The Prognosis of Severe TBI is Particularly Poor
    • 2.10.1. Numerous Complications are Associated with TBI

3. THE EPIDEMIOLOGY AND FINANCIAL IMPLICATIONS OF TBI

  • 3.1. Epidemiology of TBI in the Seven Major Markets
    • 3.1.1. Road Traffic Accidents Set To Become the Third Leading Cause of Global Disease and Disability
    • 3.1.2. The incidence of Combat-Related TBI is Rising
  • 3.2. The Financial Impact of TBI is High

4. THE CURRENT MANAGEMENT OF TBI

  • 4.1. The Management of TBI
  • 4.2. Acute Complications of Mild TBI are a Priority Concern
  • 4.3. The Management of Moderate and Severe TBI Attempts to Minimize Secondary Injury
  • 4.4. Pharmacological Treatment Forms the Cornerstone of Post TBI Complications
  • 4.5. TBI Rehabilitation Involves a Multi Therapy Approach

5. THE MAJOR CHALLENGES OF TBI RESEARCH AND DEVELOPMENT (R&D)

  • 5.1. Failure of Over 30KKKKK TBI Phase III Clinical Trials of Neuroprotectives in the Past 20KKKKK Years
  • 5.2. The Vision of TBI Research
  • 5.3. Obama's National Research Action Plan
  • 5.4. TBI Clinical Trial Challenges
    • 5.4.1. Heterogeneity of the TBI Population
    • 5.4.2. Clinical Trial Design
    • 5.4.3. International Mission on Prognosis and Clinical Trials in TBI (IMPACT) Recommendations
  • 5.5. Alternative Approaches to TBI Research
    • 5.5.1. Systems Biology Research in TBI
    • 5.5.2. Comparative Effectiveness Research in TBI
  • 5.6. The Potential of TBI Biomarkers to Aid R&D
    • 5.6.1. Proteomics-Based Biomarker Discovery in TBI
    • 5.6.2. TBI Diagnostic and Patient Monitoring Platform Development
    • 5.6.3. The Potential of Theranostics in TBI R&D
  • 5.7. TBI Regulatory Issues
  • 5.8. TBI Ethical Challenges

6. UNMET NEEDS IN THE TBI MARKET

  • 6.1. Lack of a Universally Accepted Definition of TBI
  • 6.2. Lack of a Gold-Standard TBI Diagnostic Test
  • 6.3. Under Diagnosis of Mild TBI
  • 6.4. Management of TBI is Not Standardized
  • 6.5. No Approved TBI Treatment is Available
  • 6.6. Elderly TBI Patients are Underserved
  • 6.7. Lack of Big Pharma/Biotech Investment in the TBI Arena
  • 6.8. International TBI Collaborations and Alliances are Required

7. TBI THERAPEUTIC PIPELINE ANALYSIS

  • 7.1. Introduction to the TBI Therapeutics Pipeline
  • 7.2. BHR Pharma'S BHR-100KKKKK (Progesterone)
    • 7.2.1. BHR-100's SyNAPSe Trial
  • 7.3. Teva Pharmaceuticals/Cephalon's Nuvigil (Armodafinil)
    • 7.3.1. Nuvigil's Phase II Trial Results
  • 7.4. Key Neurotek Pharmaceuticals' KN38-7271
  • 7.5. Neuren Pharmaceuticals' NNZ-2566
    • 7.5.1. NNZ-2566's Intrepid- 2566KKKKK Trial
    • 7.5.2. NNZ-2566KKKKK Oral Formulation Trials
  • 7.6. NNZ-2566'S Commercialization Potential
  • 7.7. Neurohealing Pharmaceuticals' NH001KKKKK (Apomorphine)
  • 7.8. Neurovive Pharmaceuticals' NEUROSTAT (Ciclosporin-A)
    • 7.8.1. NeuroSTAT's Clinical Trials
    • 7.8.2. NeuroSTAT's Commercialization Potential
  • 7.9. Oxygen Biotherapeutics' Oxycyte (Perflurocarbon Oxygen Carrier)
  • 7.10. Vasopharm's VAS203
    • 7.10.1. VAS203's Nostra Trial Results
  • 7.11. Remedy Pharmaceuticals' RP-1127
    • 7.11.1. RP-1127KKKKK Clinical Trials
    • 7.11.2. RP-1127KKKKK Commercialization Potential

8. OVERVIEW OF KEY ACADEMIC AND GOVERNMENTAL TBI RESEARCH

  • 8.1. Introduction to Academia and Governmental TBI Research
  • 8.2. Review of Leading TBI Pipeline Drug Classes
    • 8.2.1. Acetylcholinesterase Inhibitors
    • 8.2.2. Erythropoietin
    • 8.2.3. Growth Hormone
    • 8.2.4. Stem Cells
  • 8.3. Academic Research for the Discovery of New TBI Drug Targets
    • 8.3.1. 5-Lipoxgenase Activating Proteins (FLAP) Inhibitors
    • 8.3.2. Purinergic Receptor Antagonists
    • 8.3.3. Proinflammatory Cytokine Inhibitors
    • 8.3.4. Cysteine Protease Inhibitors
    • 8.3.5. Transcranial Delivery of Glutathione Used in Innovative Dynamic Imaging Study of Mild TBI
    • 8.3.6. Membrane Attack Complex (MAC) of the Terminal Complemental Pathway
  • 8.4. US Governmental Agency Research for the Discovery of New TBI Drug Targets
    • 8.4.1. US Department of Veterans Affairs
    • 8.4.2. US Department of Defense
    • 8.4.3. National Institute of Neurological Disorders and Stroke

9. POTENTIAL TBI BIOMARKERS

  • 9.1. Introduction to Potential TBI Biomarkers
  • 9.2. S100KKKKK B Caclcium Binding Protein
  • 9.3. Neuron Specific Enolase (NSE)
  • 9.4. Glial Fibrillary Acidic Protein (GFAP)
  • 9.5. Neurofilament Light Protein (NFL)
  • 9.6. Spectrin Breakdown Products
  • 9.7. Beta-Amyloid Protein (AB)
  • 9.8. Myelin Basic Protein (MBP)
  • 9.9. Ubiquitin Carboxyl-Terminal Hydrolase Isoenzyme L1KKKKK (UCH-L1)
  • 9.10. Tau Proteins
  • 9.11. Ampar Peptide/GLUR1
  • 9.12. TBI Biomarker Assay Services
    • 9.12.1. Grace Laboratories
    • 9.12.2. Banyan Biomarkers

10. TBI POINT OF CARE DIAGNOSTIC DEVICES PIPELINE ANALYSIS

  • 10.1. Introduction to the TBI Point of Care Diagnositc Devices Pipeline
  • 10.2. Luoxis Diagnostics/Ampio Pharmaceuticals' Redoxsys Diagnostic System
    • 10.2.1. RedoxSYS Diagnostic System's Phase III Isolated TBI Trial Results
    • 10.2.2. RedoxSYS Diagnostic System's Commercialization Potential
  • 10.3. Banyan Biomarkers' UCH-L1/GFAP Detection Assay
    • 10.3.1. UCH-L1/GFAP Detection Assay Commercialization Potential
  • 10.4. Biodirections' Tbit Test Platform
    • 10.4.1. Tbit Test Platform's Commercialization Potential
  • 10.5. SFC Fluidics' TBI Diagnostic Platforms
    • 10.5.1. SFC Fluidics' TBI Diagnostic Platforms Commercialization Potential
  • 10.6. Brainscope's Ahead M-100
    • 10.6.1. Ahead M-100's Clinical Trial Results
    • 10.6.2. Ahead M-100KKKKK Commercialization Potential
  • 10.7. Cerora's Mindreader Biosensor Biomarker Program
    • 10.7.1. Mindreader's Commercialization Potential
  • 10.8. ELMindA's BNA Platform
    • 10.8.1. BNA Platform's Commercialization Potential
  • 10.9. Neuro Assessment Systems' Neuro-Screen
    • 10.9.1. Neuro-Screen's Commercialization Potential

11. FINANCIAL FORECAST OF THE POTENTIAL TBI MARKET

  • 11.1. Arrowhead's Analysis of the Potential Therapeutic TBI Market
  • 11.2. Analysis of the Potential TBI POC Diagnostic Devices Market
  • 11.3. SWOT Analysis of the Potential TBI Market
  • 11.4. Summary of the Potential TBI Market

12. COMPANY BRIEFS

  • 12.1. Banayan Biomarkers Inc.
  • 12.2. BHR Pharma LLC
  • 12.3. Biodirection Inc.
  • 12.4. Brainscope Company Inc.
  • 12.5. Cerora Inc.
  • 12.6. ElMindA Ltd.
  • 12.7. Grace Laboratories LLC
  • 12.8. KeyNeurotek Pharmaceuticals AG
  • 12.9. Luoxis Diagnostics
  • 12.10. Neuro Assessment Systems
  • 12.11. Neurohealing Pharmaceuticals
  • 12.12. Neuren Pharmaceuticals Ltd.
  • 12.13. Neurovive Pharmaceuticals AB
  • 12.14. Oxygen Biotherapeutics Inc.
  • 12.15. Phlogistix LLC
  • 12.16. Remedy Pharmaceuticals Inc.
  • 12.17. SFC Fluidics LLC
  • 12.18. TEVA Pharmaceutical Industries Ltd.
  • 12.19. Vasopharm

13. BIBLIOGRAPHY

List of Tables

  • Table 1: TBI Incidence Forecast in 2014 and 2020 in the Seven Major Markets
  • Table 2: TBI Pipeline Candidates Undergoing Late-Stage Clinical Development by Pharma/Biotech Companies
  • Table 3: Late-stage TBI POC Diagnostic Devices Pipeline, Jan 2014
  • Table 4: Financial Forecast of the Potential TBI Market, in 2014 and 2020 in the US and EU ($ billions)
  • Table 5: The Glasgow Coma Score
  • Table 6: The Ranchos Los Amigos Scale
  • Table 7: Summary of TBI Severity Stratification
  • Table 8: The Glasgow Outcome Scale
  • Table 9: The Disability Rating Scale
  • Table 10: The Disability Rating Scale Prognosis Outcome
  • Table 11: Complications Associated with TBI
  • Table 12: Crude Incidence Rate of TBI (per 100,000) in the Seven Major Markets, 2014
  • Table 13: TBI Incidence Forecast in the Seven Major Markets, 2014-2020
  • Table 14: Mild TBI Incidence Forecast in the Seven Major Markets, 2014-2020
  • Table 15: Moderate TBI Incidence Forecast in the Seven Major Markets, 2014-2020
  • Table 16: Severe TBI Incidence Forecast in the Seven Major Markets, 2014-2020
  • Table 17: Brain Trauma Foundation Guidelines for the Acute Management of Severe TBI
  • Table 18: Management of Common Post-TBI Complications
  • Table 19: Failed Phase III Clinical Trials of Novel Neuroprotectives in Moderate and Severe TBI over the Past 30 Years
  • Table 20: National Research Action Plan Deadline Targets in TBI
  • Table 21: IMPACT Recommendations for the Use of Common Outcome Measures in TBI
  • Table 22: Applications of TBI Diagnostic and Patient Monitoring Platforms
  • Table 23: Incentives Granted to Orphan Drug Developers
  • Table 24: TBI Therapeutic Pipeline, Jan 2014
  • Table 25: Comparison of ProTECT II and Xiao Clinical Trials
  • Table 26: Comparison of SyNAPSe and ProTECT III Clinical Trials
  • Table 27: TBI Point- of-Care Diagnostic Devices Pipeline, Jan 2014
  • Table 28: Arrowhead's Financial Forecast of the Potential Therapeutic TBI Market in the US and EU, 2014-2020 ($ millions)
  • Table 29: Arrowhead's Financial Forecast of the Potential TBI POC Diagnostic Devices Market in the US and EU, 2014-2020 ($ millions)
  • Table 30: Arrowhead's Financial Forecast of the Potential TBI Market in the US and EU, 2014-2020 ($ billions)

List of Figures

  • Figure 1: TBI Incidence Forecast in 2014 and 2020 in the Seven Major Markets
  • Figure 2: Major Unmet Needs in TBI
  • Figure 3: Finanical Forecast of the Potential TBI Market, in 2014 and 2020 in the US and EU ($ billions)
  • Figure 4: The Anatomy of the Human Brain
  • Figure 5: Cause of all TBIs within the US General Population, 2010
  • Figure 6: The Pathophysiological Pathways Involved in Secondary Brain Injury
  • Figure 7: TBI Patient Population by Brain Injury Severity
  • Figure 8: TBI Incidence Forecast in the Seven Major Markets, 2014-2020
  • Figure 9: Mild TBI Incidence Forecast in the Seven Major Markets, 2014-2020
  • Figure 10: Moderate TBI Incidence Forecast in the Seven Major Markets, 2014-2020
  • Figure 11: Severe TBI Incidence Forecast in the Seven Major Markets, 2014-2020
  • Figure 12: Info graphic on Global Road Traffic Accidents
  • Figure 13: Number of Persons Injured in a Road Traffic Accident within the US, 2000-2011
  • Figure 14: Total Worldwide Number of TBIs Diagnosed in US Military Personnel, 2000-2012
  • Figure 15: The Total Worldwide Number of Combat-Related TBIs Diagnosed in US Military Personnel, 2000-2012
  • Figure 16: Management Algorithm of TBI According to Glasgow Coma Score
  • Figure 17: NRAP's Approach to Address the Current Unmet Needs in TBI R&D
  • Figure 18: The Use of Biomarkers to Maximize TBI R&D
  • Figure 19: Systems Biology-Based Selection of Potential TBI Biomarkers,
  • Figure 20: Number of Phase III Randomized Controlled Trials in Moderate and Severe TBI per Five -Year Time Period Between1980 to 2005
  • Figure 21: Potential TBI Biomarkers
  • Figure 22: Illustrative of BNA Platform's Brain Network Activation Patterns
  • Figure 23: Arrowhead's Financial Forecast of the Potential Therapeutic TBI Market in the US and EU, 2014-2020 ($ millions)
  • Figure 24: Arrowhead's Financial Forecast of the Potential TBI Therapeutics Market in the US and EU, 2014-2020 ($ millions)
  • Figure 25: SWOT Analysis of the TBI Market, 2014
  • Figure 26: Arrowhead's Financial Forecast of the Potential TBI Market in the US and EU, 2014-2020 ($ billions)
Back to Top